Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900387 | 0.89 | KDR (0.42) | PLA2G7SCN9ABRAFKDR | |
| SCHEMBL875765 | 0.87 | ALDH1A1 (0.41) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL876023 | 0.79 | KCNH2 (0.39) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL9901028 | 0.77 | PLA2G7 (0.38) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL875574 | 0.76 | KDR (0.44) | CDK8PLA2G7SCN9ABRAFKDR | |
| SCHEMBL876035 | 0.76 | CDK8 (0.45) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL13531352 | 0.73 | TRPA1 (0.43) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL23771636 | 0.71 | AGER (0.53) | KCNH2HTR2ASLC6A4 | |
| SCHEMBL17467929 | 0.71 | ALDH1A1 (0.63) | KCNH2HTR2ASLC6A4CDK8PLA2G7 | |
| SCHEMBL248689 | 0.71 | TRPA1 (0.45) | KCNH2HTR2ASLC6A4CDK8BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | KCNH2 4023/4885HTR2A 2268/4885SLC6A4 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.